Journal: EJIFCC

Article Title: Soluble ST2 and Galectin-3: What We Know and Don’t Know Analytically

doi:

Figure Lengend Snippet: Information on selected commercially available assays for measurement of sST2 and galectin-3 in human serum/plasma

Article Snippet: MBL International ( www.mblintl.com) , Human ST2 ELISA kit , 0.032 ng/mL , up to 20 ng/mL , <6%.

Techniques: Inter Assay, Enzyme-linked Immunosorbent Assay

Journal: EJIFCC

Article Title: Soluble ST2 and Galectin-3: What We Know and Don’t Know Analytically

doi:

Figure Lengend Snippet: Data on an analytical assay comparison of the Presage ST2 assay, the MBL ST2 assay, and a R&D ST2 assay *

Article Snippet: MBL International ( www.mblintl.com) , Human ST2 ELISA kit , 0.032 ng/mL , up to 20 ng/mL , <6%.

Techniques: Comparison, Clinical Proteomics

Journal: EJIFCC

Article Title: Soluble ST2 and Galectin-3: What We Know and Don’t Know Analytically

doi:

Figure Lengend Snippet: Panel A represents the H000 SR compared to the ELISA at site A; Panel B represents the i2000 SR compared to the ELISA at site A; Panel C represents the i2000 SR compared to the ELISA at site B; Panel D represents the combined i2000 SR data from site A and B compared to the ELISA. A total of 190 samples at site A and 129 samples at site B were analyzed. The grey line represents x=y and the solid black line indicates the Passing-Bablok regression line. Equitations of the regression line and correlation coefficients are shown. Adopted from .

Article Snippet: MBL International ( www.mblintl.com) , Human ST2 ELISA kit , 0.032 ng/mL , up to 20 ng/mL , <6%.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Journal of Inflammation (London, England)

Article Title: Association of intestinal and systemic inflammatory biomarkers with immune reconstitution in HIV+ patients on ART

doi: 10.1186/s12950-020-00262-4

Figure Lengend Snippet: Systemic immune activation, inflammation, microbial translocation, proinflammatory cytokines, intestinal damage and inflammation biomarkers

Article Snippet: Serum concentration of Intestinal Fatty Acids-Binding Protein (I-FABP) and the soluble IL-33 receptor sST2 were measured by ELISA (Human Intestinal Fatty Acid Binding Protein I-FABP ELISA kit; CUSABIO, Houston, TX, USA and Human ST2/IL-33R Quantikine ELISA kit, R&D Systems, Minneapolis, MN, USA), following each manufacturer protocols.

Techniques: Activation Assay, Translocation Assay, Expressing

Journal: Journal of Inflammation (London, England)

Article Title: Association of intestinal and systemic inflammatory biomarkers with immune reconstitution in HIV+ patients on ART

doi: 10.1186/s12950-020-00262-4

Figure Lengend Snippet: Determination of gut damage and inflammation. a I-FABP, b sST2, c Fecal lactoferrin, d Fecal calprotectin, e sIgA, f Association between I-FABP levels and Lipopolysaccharide concentration, g Association between fecal calprotectin levels and absolute CD4 + T-cells count, h Association between fecal calprotectin levels and duration of HIV infection and i Association between fecal calprotectin levels and duration of antiretroviral treatment. Kruskall-Wallis test with Bonferroni correction. Data show as median (IQR); * p < 0.05 . Spearman correlation test

Article Snippet: Serum concentration of Intestinal Fatty Acids-Binding Protein (I-FABP) and the soluble IL-33 receptor sST2 were measured by ELISA (Human Intestinal Fatty Acid Binding Protein I-FABP ELISA kit; CUSABIO, Houston, TX, USA and Human ST2/IL-33R Quantikine ELISA kit, R&D Systems, Minneapolis, MN, USA), following each manufacturer protocols.

Techniques: Concentration Assay, Infection

Journal: Frontiers in Molecular Biosciences

Article Title: Identification of novel candidate targets for suppressing ovarian cancer progression through IL-33/ST2 axis components using the system biology approach

doi: 10.3389/fmolb.2023.1189527

Figure Lengend Snippet: Expression of IL-33 and ST2 in CAFs. (A,B) Expression of IL-33 and ST2 genes/mRNAs in the CAFs in the patient and healthy groups as assessed by qRT-PCR. (C,D) Expression of IL-33 and ST2 genes in the epithelial cells of the patient and healthy groups as assessed by qRT-PCR. (E) Expression of IL-33, ST2, and sST2 protein in the CAFs of the patient and healthy groups as assessed by western blotting. (F) The concentration of IL-33 and sST2 was measured by ELISA assays in the CAFs, healthy, and serum. (G) Expression of IL-33, ST2, and sST2 protein in the epithelial cells of the patient and healthy groups as assessed by western blotting. (H) The concentration of IL-33 and sST2 was measured by ELISA assays in the EPT, healthy, and serum.* p < 0.05 and ** p < 0.01.

Article Snippet: For sST2 estimation, we used the Human ST2 ELISA Kit (Biorbyt Ltd., Cambridge, United Kingdom, product number: orb219434), and for the measurement of IL-33, the Human IL-33 ELISA Kit (Biorbyt Ltd., Cambridge, United Kingdom, product number: orb390944) was used.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Concentration Assay, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Molecular Biosciences

Article Title: Identification of novel candidate targets for suppressing ovarian cancer progression through IL-33/ST2 axis components using the system biology approach

doi: 10.3389/fmolb.2023.1189527

Figure Lengend Snippet: (A) Acetylation rate at the promoter of IL-33 and ST2 genes in CAFs, EPT, and healthy cells. (B) Immunohistochemical staining of IL-33 and ST2 in the OvC tissue showed the presence of ST2 and IL-33 in both epithelial cells and cancer-associated fibroblasts. (C) Representative image of immunohistochemistry of α-SMA and E-cadherin (in brown) from healthy and tumor samples from OvC patients (objective ×20). Blue arrowheads indicate positive cells in healthy, black arrows heads indicate E-cadherin positive tumor cells, and red arrowheads indicate α-SMA positive stromal cells. (D) Contribution of the IL-33 and T2 protein. (E) Comparison of IL-33 and ST2 genes abundance in tumor epithelial cells and CAFs as determined by qRT-PCR. (F) Comparison of ST2 and IL-33 protein abundance in CAFs and epithelial cells as determined by western blotting. (G) Comparison of ST2 and IL-33 protein concentrations in CAFs and epithelial cells as determined by ELISA. Contribution of the IL-33 and T2 protein. Data are mean ± SEM. * p < 0.02 and ** p < 0.01.

Article Snippet: For sST2 estimation, we used the Human ST2 ELISA Kit (Biorbyt Ltd., Cambridge, United Kingdom, product number: orb219434), and for the measurement of IL-33, the Human IL-33 ELISA Kit (Biorbyt Ltd., Cambridge, United Kingdom, product number: orb390944) was used.

Techniques: Immunohistochemical staining, Staining, Immunohistochemistry, Comparison, Quantitative RT-PCR, Quantitative Proteomics, Western Blot, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Molecular Biosciences

Article Title: Identification of novel candidate targets for suppressing ovarian cancer progression through IL-33/ST2 axis components using the system biology approach

doi: 10.3389/fmolb.2023.1189527

Figure Lengend Snippet: Role of ST2 in the induction of COX-2, IL-6, and IL-1β by IL-33 in CAFs. (A) Effects of ST2 siRNA-mediated knockdown on the protein abundance by IL-33. (B) Effects of siRNA-mediated knockdown of ST2 on the induction of COX-2, IL-6, and IL-1β and phosphorylation of p38, ERK1/2, JNK, and p65 by IL-33 (100 ng/mL; 1.5 h). * p < 0.05, ** p < 0.01, and *** p < 0.001.

Article Snippet: For sST2 estimation, we used the Human ST2 ELISA Kit (Biorbyt Ltd., Cambridge, United Kingdom, product number: orb219434), and for the measurement of IL-33, the Human IL-33 ELISA Kit (Biorbyt Ltd., Cambridge, United Kingdom, product number: orb390944) was used.

Techniques: Knockdown, Quantitative Proteomics, Phospho-proteomics